medigraphic.com

2013, Número S1

<< Anterior Siguiente >>

Rev Mex Anest 2013; 36 (S1)


Actualidades en hipertermia maligna

Carrillo-Esper R, Lázaro-Santiago G, Nava-López JA

Idioma: Español
Referencias bibliográficas: 18
Paginas: 307-309
Archivo PDF: 72.34 Kb.


FRAGMENTO

La hipertermia maligna (HM) en un desorden genético complejo del sistema musculoesquelético que se manifiesta típicamente como una crisis de hipermetabolismo, cuando pacientes susceptibles reciben algún tipo de medicamentos, generalmente de uso anestésico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kim D. Malignant hyperthermia. Korean J Anesthesiol. 2012;63:391-401.

  2. Bandschapp O, Girard T. Malignant hyperthermia. Swiss Medical Weekly. 2012;142:1-4.

  3. McCarthy E. Malignant hyperthermia, pathophysiology, clinical presentation and treatment, AACN Clinical Issues. 2004;15:231-237.

  4. Patil P, Pradesh U. Malignant hyperthermia in the oral and maxillofacial surgery patient: an update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112:e1-e7.

  5. Benkusky N, Farrell E, Valdivia H. Ryanodine receptor channelopathies. Biochemical and Biophysical Research Communications. 2004;322:1280-1285.

  6. Denborough M. Malignant hyperthermia. The Lancet. 1998;352:1131-1136.

  7. Rosenberg H, Rueffert H. Clinical utility gene card for: malignant hyperthermia. European Journal of Human Genetics. 2011;19:1-4.

  8. Petegem F. Ryanodine receptors: structure and function. The Journal of Biological Chemistry. 2012;287:31624-31632.

  9. Lanner J, Georgiou D, Joshi A, Hamilton S. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol. 2010;2:1-21.

  10. Anderson A, Brown R, Polster B, Pollock N, Stowell K. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. Anesthesiology. 2008;108:208-215.

  11. Correia A, Silva P, Silva B. Hipertermia maligna: aspectos moleculares y clínicos. Rev Bras Anestesiol. 2012;62:1-10.

  12. Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. Anesth Analg. 2009;109:1049-1053.

  13. Hirshey Dirksen SJ, Larach MG, Rosenberg H, Brandom BW, Parness J, Lang RS, et al. Special article: Future directions in malignant hyperthermia research and patient care. Anesth Analg. 2011;113:1108-1119.

  14. Christiansen L, Collins K. Pathologic findings in malignant hypertermia, A case report and review of literature. The American Journal of Forensic Medicine and Pathology. 2004;25:327-333.

  15. Payen de la Garanderie JF, Depret T, Monnier N, Nivoche Y, Lunardi J, Krivosic-Horber R. Hipertermia Maligna. EMC (Elsevier Masson SAS, Paris), Anesthésie-Réanimation. 2004;36-412-E-10.

  16. Elias G, Venegas A. Hipertermia maligna. Acta Pediátrica de Mexico. 1996;17:45-48.

  17. Rosenberg H, Davis M, James D, Pollock N, Stowell K. MalignanT hyperthermia. Orphanet Journal of Rare Diseases. 2007;2:21:1-14.

  18. Wappler F. Anesthesia for patients with a history of malignant hyperthermia. Current Opinion in Anaesthesiology. 2010;23:417-422.




2020     |     www.medigraphic.com